Shopping Cart![[Library House]](/images/lh/logos/lh_logo_white_strap.gif){kind=logo}
Print
BookmarkCompany Profile
A Library House company profile provides a dynamic, essential view of a fast growth, venture-backed private company. The profile contains information that can assist you in evaluating competitors, opportunities, partnerships and customers.
Library House discovers, researches and profiles over 8,000 privately-held companies on a continuous basis, providing a unique tracking service for privately-held companies.
Company profiles can be purchased individually, or viewed as part of a subscription to the full database.
Paradigm Therapeutics
Legal Name: Paradigm Therapeutics Ltd
Summary
|
Paradigm Therapeutics Ltd is a drug target discovery and development company, turning human gene sequences into validated drug targets. Areas of focus include CNS, pain, endocrinology and metabolism. The genomics-based drug discovery company uses several research methods including model mouse genetics, bioinformatics, and molecular biology to identify genes that may serve as drug targets (1).
The company claims to be a world leader in the use of functional genetics utilising mouse KO technology, and has established a pipeline of patent protected, small molecule tractable targets with defined therapeutic utility such as G-protein coupled receptors (GPCRs), ion channels, proteases and transporters. As of Q4 2005, the company website stated that the company had identified over 1000 potential drugable targets, of which more than a quarter were undergoing biological validation.
Source: Library House
Location and Contacts
| Company Headquarters: |
|
|
| Region: | East of England | |
| Other Offices: |
Biopolis, Singapore |
|
| Contact: | Dr Alastair Riddell | |
| Email Address: | ariddell@paradigm-therapeutics.co.uk | |
| Website: | www.paradigm-therapeutics.co.uk |
Classification
| FTSE Sector: |
Health Care > Health Care > Pharmaceuticals & Biotechnology |
| FTSE Target Customer Sector: |
Health Care > Health Care > Pharmaceuticals & Biotechnology |
| LH Sector: |
Healthcare & Life Sciences > Pharmaceuticals & Drug Development |
| LH Tags: |
Technology Tags > Healthcare & Life Sciences > Pharmaceuticals & Drug Development > Pharmaceuticals Agent Type > Protein-based (Not Antibody) Technology Tags > Healthcare & Life Sciences > Medical Tags > Medical Indication > Metabolic Disorders (Including Diabetes & Obesity) Technology Tags > Healthcare & Life Sciences > Medical Tags > Medical Indication > Neurology & Pain (CNS) |
Latest News
| Date | Headline | Source |
|---|---|---|
|
|
Takeda to acquire Paradigm Therapeutics
Takeda Pharmaceutical Company Limited (“Takeda”) today announced that Takeda and Paradigm Therapeutics Limited (“Paradigm”) agreed on March 12, 2007 to the acquisition of Paradigm by Takeda. Paradigm shareholders were advised by Avlar BioVentures Limited. Financial terms were not disclosed. Subject to completion, which is expected to occur within a few weeks, Paradigm will become a subsidiary of Takeda Europe Holdings B.V., a wholly owned subsidiary of Takeda. Additionally, Paradigm wil... » MorePlease note that Library House is not responsible for the content of external web sites. |
Company Press Release |
|
|
Paradigm Therapeutics raises £7m in fourth funding round
Paradigm Therapeutics Limited (“Paradigm”) today announces the successful completion of a fourth round of private equity funding totalling approximately £7 million from its existing investors, Avlar BioVentures, Bio*One Capital, Merlin Biosciences and Lloyds TSB Development Capital. Commenting on the funding, Dr. Alastair Riddell, Chief Executive Officer, said: “I am delighted that our major investors have shown their continued support for the Company. This investment, combined with the... » MorePlease note that Library House is not responsible for the content of external web sites. |
Company Press Release |
|
|
Paradigm Therapeutics appoints Dr Alastair as Riddell as chief executive
Dr Riddell was formerly the CEO and main board member of Pharmagene plc for seven years, where he raised £8.6 million in a private placement in 1999 and £41.7 million at IPO in July 2000. He has held senior positions in international marketing, sales and general management in Amersham International and Centocor. He previously directed the medical departments of Celltech and Centocor Europe. He is currently BIA Deputy Chairman and has been a member of the executive board of the BIA for 3 ye... » MorePlease note that Library House is not responsible for the content of external web sites. |
Company Press Release |
|
|
Paradigm Therapeutics acquires Amedis Pharmaceuticals | ERBI Website |
| Page: 1 | ||
Key Financials
Data
|
Dec 03 12 months |
Dec 04 12 months |
Dec 05 12 months |
Dec 06 12 months |
|
|---|---|---|---|---|
|
|
- | - | 597 | 1,020 |
|
|
|
|
|
|
| Headcount | 26 | 38 | 52 | 63 |
Capital History
Investment History:
| Date | Stage | Amount (000) | Investor | |
|---|---|---|---|---|
| Q2 1999 | Undisclosed | Wellcome Trust, Avlar BioVentures Ltd (Cambridge Gateway Fund), Mark Carlton, Samuel Aparico, Cambridge University, Self Funded | ||
| Q4 2002 | 12,000 | Biomedical Sciences Investment Fund, Avlar BioVentures Ltd (Cambridge Gateway Fund), Lloyds TSB Development Capital | ||
| Q1 2005 | 5,500 | Bio*One Capital Pte Ltd, Merlin Biosciences, Avlar BioVentures Ltd (Cambridge Gateway Fund) | ||
| Q3 2006 | 7,000 | Lloyds TSB Development Capital, Merlin Biosciences, Bio*One Capital Pte Ltd, Avlar BioVentures Ltd (Cambridge Gateway Fund) [1] |
Acquisition Activity:
| Date | Target | Stage | Amount (000) | Investor |
|---|---|---|---|---|
| Q1 2005 | Amedis Pharmaceuticals | Trade Sale | Undisclosed | Paradigm Therapeutics [2] |
| Q1 2007 | Paradigm Therapeutics | Trade Sale | Undisclosed | Takeda Pharmaceutical Company |
| Total: | 0 | |||
Notes
| [1] | The investment was to allow the company to take its first product to the clinical proof of concept stage and achieve its first licensing deal. |
| [2] | Paradigm said, in a company report (07/01/2005), that it would use this acquisition to form a larger company. The enlarged company would have cash reserves of GBP 11m, of which half would be from new investment made by existing Paradigm shareholders. Further financial details of the acquisition were not disclosed. |
Current Management Team
| Name | Role | Joined | Other Roles | Past Roles |
|---|---|---|---|---|
| Alan Munro | Non Executive Chairman | Not Set | - | - |
| Dr Rony Douek | Non-Executive Director | Not Set | - | - |
| Dr Alastair Riddell | Chief Executive Officer | 18th May 2005 | - | - |
| Dr Graham Showell (46) | Director, Chemistry | Not Set | 1 | - |
| Dr Ian Gray | Director, R&D | Not Set | - | - |
| Dr Mark Carlton (43) | Chief Operating Officer | Not Set | - | - |
| Dr Barry Kenny (45) | Commercial Director | Not Set | - | - |
| Jim Sutcliffe (41) | Finance Manager | Not Set | - | - |
Former Management Team
| Name | Role | Leaving Date | Other Roles | Past Roles |
|---|---|---|---|---|
| Dr Edwin Moses (54) | Executive Chairman | 30th Mar 2006 | 5 | - |
| Dr John Montana | Chief Scientific Officer | 30th Nov 2005 | - | - |
Company Origins
| Origin Name | Type | Date | Description |
|---|---|---|---|
| Cambridge University | University Spin-Out | Jun 1998 | Paradigm Therapeutics Ltd was a spinout of Cambridge University |
Customers & Partners
| Name | Type |
|---|---|
| Genmab | Partner |
| Medivir | Partner |
| Takeda | Partner |
| Ortho-McNeil Pharmaceuticals | Partner |
| Cytomyx | Partner |
![[Library House]](/images/lh/logos/lh_logo_white.gif){kind=logo}
